Tag Archives: PFE stock research

Pfizer (PFE) reported 24Q4 revenues of $17.8 billion, up 24.7% from 23Q4 and 3.4% above my estimate.  Sales of  Comirnaty were much stronger than expected, but that was mostly offset by lower than projected sales of Paxlovid.  GAAP EPS was … Continue reading →